These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 36041474)

  • 21. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
    Bhatt AS; Bhatt DL; Steg PG; Szarek M; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Testani JM; Wilcox CS; Davies M; Pitt B; Kosiborod MN
    J Am Coll Cardiol; 2024 Sep; 84(12):1078-1088. PubMed ID: 39260929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
    Banerjee M; Pal R; Nair K; Mukhopadhyay S
    Indian Heart J; 2023; 75(2):122-127. PubMed ID: 36914068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    McMurray JJV; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Anand IS; Bělohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett JG; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Petrie MC; Vinh PN; Schou M; Tereshchenko S; Verma S; Held C; DeMets DL; Docherty KF; Jhund PS; Bengtsson O; Sjöstrand M; Langkilde AM;
    N Engl J Med; 2019 Nov; 381(21):1995-2008. PubMed ID: 31535829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
    Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
    Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Kosiborod MN; Deanfield J; Pratley R; Borlaug BA; Butler J; Davies MJ; Emerson SS; Kahn SE; Kitzman DW; Lingvay I; Mahaffey KW; Petrie MC; Plutzky J; Rasmussen S; Rönnbäck C; Shah SJ; Verma S; Weeke PE; Lincoff AM;
    Lancet; 2024 Sep; 404(10456):949-961. PubMed ID: 39222642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure.
    Packer M; Butler J; Filippatos G; Zannad F; Ferreira JP; Zeller C; Brueckmann M; Jamal W; Pocock SJ; Anker SD;
    Eur J Heart Fail; 2020 Dec; 22(12):2393-2398. PubMed ID: 33251659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
    Starr JA; Pinner NA
    Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
    Kondo T; Butt JH; Curtain JP; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
    Circ Heart Fail; 2023 Dec; 16(12):e010898. PubMed ID: 37886880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure.
    Vaduganathan M; Claggett BL; Jhund P; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2022 Nov; 80(19):1775-1784. PubMed ID: 36041669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
    Solomon SD; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Lindholm D; Wilderäng U; Öhrn F; Claggett B; Langkilde AM; Petersson M; McMurray JJV
    Eur J Heart Fail; 2021 Jul; 23(7):1217-1225. PubMed ID: 34051124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
    Vaduganathan M; Claggett BL; Jhund P; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Hegde SM; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    JAMA Cardiol; 2022 Dec; 7(12):1259-1263. PubMed ID: 36190011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum.
    Butt JH; Docherty KF; Claggett BL; Desai AS; Fang JC; Petersson M; Langkilde AM; de Boer RA; Cabrera Honorio JW; Hernandez AF; Inzucchi SE; Kosiborod MN; Køber L; Lam CSP; Martinez FA; Ponikowski P; Sabatine MS; Vardeny O; O'Meara E; Saraiva JFK; Shah SJ; Vaduganathan M; Jhund PS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2023 Apr; 11(4):375-388. PubMed ID: 36881399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.
    Cardoso R; Graffunder FP; Ternes CMP; Fernandes A; Rocha AV; Fernandes G; Bhatt DL
    EClinicalMedicine; 2021 Jun; 36():100933. PubMed ID: 34308311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
    J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
    JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.
    Razuk V; Chiarito M; Cao D; Nicolas J; Pivato CA; Camaj A; Power D; Beerkens F; Jones D; Alter A; Mathew A; Spirito A; Contreras JP; Dangas GD; Mehran R
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):557-567. PubMed ID: 35021205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of SGLT2 inhibitors (gliflozins) in heart failure].
    Scheen AJ; Ancion A; Lancellotti P
    Rev Med Suisse; 2022 Aug; 18(792):1546-1550. PubMed ID: 36004654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial.
    Peikert A; Bart BA; Vaduganathan M; Claggett BL; Kulac IJ; Kosiborod MN; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD; Vardeny O
    JACC Heart Fail; 2024 Apr; 12(4):631-644. PubMed ID: 37767674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.